5th Edition MarketsandMarkets

Real-World Data, Life Sciences Analytics and Market Access Virtual Conference (Time Zone - Eastern Standard Time (EST)

20th- 22nd October 2021

MarketsandMarkets is proud to announce the 5th Edition Real-World Data, Life Sciences Analytics and Market Access – Virtual Conference to be held on October 20-22, 2021. The expanding utilization of Real World Evidence to speed up data driven choices is further developing the clinical trial experience, but healthcare in general. 

While there is extraordinary promise in utilizing Real World Data and Real World Evidence, there are some significant challenges that should be survived: potential bias of information and data sources, inadequate data sets and absence of harmonization of data between RWE data sources, access to such data, and lack of standards in evaluating the worth of Real World Evidence data. Further developing RWE is key for pharma organizations in drug development. There was big data available pre covid and now with the access data due to covid, technology enablers like AI and ML are important for big data analysis and evidence generation. Every stakeholder has faced a some impact and had to adjust. 

Tag Line
Learn how adoption of real-world evidence can be accelerated across pharmaceutical industry
Tag Line
Explore capabilities of using Artificial Intelligence & Machine Learning in taming scientific research
Tag Line
Understand the impact of innovative real-world evidence partnerships for better data

This conference will focus on above said significant challenges and hold discussion on the best practices adopted by various stakeholders with a key takeaway being better decision making. 

WHAT TO EXPECT

  • Clinical trial protocol design
  • Impact of covid on clinical trial design
  • Patients focussed drug development
  • Reimbursement schemes during the era of covid- Has it changed?
  • Partnering strategies
  • Technology enablers-Artificial Intelligence and Machine Learning for big data analytics
  • RWE in rare diseases space helping to achieving the required approvals
  • Patient identification- An important aspect of real world evidence

  • Learn about the recent trends and advancements in Real-World Evidence Generation
  • Engage in meaningful discussion with the most prominent industry experts and decision makers from pharmaceutical and biopharmaceutical companies who will address most critical challenges in real-world data and real-world evidence space.
  • Opportunity to network and exchange scientific knowledge with expert speakers from leading pharmaceutical companies, global regulators, and solution providers

From Pharmaceutical and Biopharmaceutical companies

Chief executives, VP’s, Directors, Global heads, Heads, Leaders, Senior Managers, Researcher, Analysts, Investigators, Scientists, Bio-Statisticians, Epidemiologists, within the following departments-

  • Real-World Evidence
  • Health Economics & Outcomes Research
  • Market Access
  • Value Access
  • Clinical Outcomes
  • Clinical Development
  • Center for Observational and Real-World Evidence  

CONFERENCE AGENDA

Registration

 09:00 - 09:20

Welcome note from MarketsandMarkets

 09:20 - 09:25

Opening Remarks from the Chairman

David Miller

David Miller, Executive Director, Head of RWE- Patient Safety, Sarepta Therapeutics, USA

 09:25 - 09:30

RELATIONSHIP BETWEEN REAL WORLD DATA AND CLINICAL TRIALS

Keynote Presentation - Challenges and opportunities on generating “regulatory grade” Real World Evidence

David Miller

David Miller, Executive Director, Head of RWE- Patient Safety, Sarepta Therapeutics, USA

 09:30 - 10:00

Propelling research and healthcare collaboration for improved consumer experience

Sharad Khusal

Sharad Khusal, Account Executive, Dedalus Group

 10:00 - 10:30

One to one networking break

10:30 - 10:50

Panel Discussion- COVID Vaccines in the Real World: what the data have taught scientists?

 10:50 - 11:30

Technology enablers-Using Artificial Intelligence and Machine Learning in context of generating evidence

Real-World Comparative Effectiveness Analysis for Use in Cost-effectiveness Modeling in Multiple Sclerosis

William L Herring

William L Herring, Senior Director, Health Economics, RTI Health Solutions

 11:30 - 12:00

Identification of disease progression stages in patients with Duchenne Muscular Dystrophy using administrative claims supplemented by relevant electronic medical records in the United States and provide real-world perspective on healthcare resource utilization and significant disease progression events in patients treated with eteplirsen.

Joel Iff

Joel Iff, Senior Director Global Market Access, Sarepta Therapeutics, USA

 12:00 - 12:30

Closing remarks from the chairperson

 12:30 - 12:35

One to one networking break

 12:35 - 12:35

End of Day 1

 12:35 - 12:35

Registration

 08:15 - 08:50

Welcome note from MarketsandMarkets

 08:50 - 08:55

Opening Remarks from the Chairman

David Miller

David Miller, Executive Director, Head of RWE- Patient Safety, Sarepta Therapeutics, USA

 08:55 - 09:00

REAL WORLD EVIDENCE- IMPORTANCE OF NEW INDICATIONS AND PATIENT CENTRICITY

Harnessing medical information insights to inform strategy and customer centricity in Pharma and Biotech

Michelle Bridenbaker

Michelle Bridenbaker, Global Medical Information Lead, Idorsia Pharmaceuticals

 09:00 - 09:30

How AI helped AstraZeneca gain insights into the Belgian Heart Failure population in record time

Georges De Feu

Georges De Feu, Founder & CEO, Lynxcare

 09:30 - 10:00

Overcoming Racial Disparities in Clinical Trials With Real-World Data

Usha Periyanayagam

Usha Periyanayagam, Head of Clinical Product and RWE, Komodo Health

 10:00 - 10:30

One to one networking break

 10:30 - 10:50

Finding the Right Patient: The Role of Advanced Patient Finding for Clinical Trials, Market Access and Clinical Practice

Richard Gliklich

Richard Gliklich, MD & CEO, OM1

 10:50 - 11:20

Data Landscaping – a good way to understand distribution, access, and quality of RWD across the globe, a renal example

Frank Liu

Frank Liu, Senior Director, North America Evidence and Value Development (NEVD), EMD Serono

 11:20 - 11:50

Closing remarks from the Chairperson

 11:50 - 11:55

One to one networking break

 11:55 - 11:55

End of Day 2

 11:55 - 11:55

Registration

 08:15 - 08:50

Welcome note from MarketsandMarkets

 08:50 - 08:55

Opening Remarks from the Chairman

David Miller

David Miller, Executive Director, Head of RWE- Patient Safety, Sarepta Therapeutics, USA

 08:55 - 09:00

MARKET ACCESS, PRICING & REIMBURSEMENT

Patient Identification and digital RWE generation in Post-partum depression

Melva Covington

Melva Covington, Principal, AGAPE Strategic Solutions LLC

 09:00 - 09:30

Patient-centricity: more than just a talking point - empowering patients and setting the bar for real-world evidence generation

Andrew Larsen

Andrew Larsen, Director of Life Sciences Partnership, PicnicHealth

 09:30 - 10:00

COVID-19 Related Guidance Documents: Understanding Potential Implications for the Conduct of Real World Studies

Nneka Onwudiwe

Nneka Onwudiwe, Former PRO/PE Regulatory Review Officer, FOOD AND DRUG ADMINISTRATION

 10:00 - 10:30

One to one networking break

 10:30 - 10:50

External Control Arms (ECAs): complementary evidence for regulatory decision-making

Jennifer Polinski

Jennifer Polinski, Vice President, Science, Aetion

 10:50 - 11:20

Unlocking the Potential for Big Data and Artificial Intelligence in Augmenting Healthcare

Prasun Mishra

Prasun Mishra, Founding Director, Chairman of the Board, Agility Pharmaceuticals

 11:20 - 11:50

Closing remarks from the Chairperson

 11:50 - 11:55

One to one networking break

 11:55 - 11:55

End of Conference

 11:55 - 11:55

CONFERENCE SPEAKERS

ADVISORS

Nneka Onwudiwe

Nneka Onwudiwe

Former PRO/PE Regulatory Review Officer, FOOD AND DRUG ADMINISTRATION

David Miller

David Miller

Executive Director, Head of RWE- Patient Safety, Sarepta Therapeutics, USA

SPEAKERS

Nneka Onwudiwe

Nneka Onwudiwe

Former PRO/PE Regulatory Review Officer, FOOD AND DRUG ADMINISTRATION

Michelle Bridenbaker

Michelle Bridenbaker

Global Medical Information Lead, Idorsia Pharmaceuticals

Tao Fan

Tao Fan

Senior Director, US HEOR US Medical Office , Takeda Pharmaceuticals

Melva Covington

Melva Covington

Principal, AGAPE Strategic Solutions LLC

Joel Iff

Joel Iff

Senior Director Global Market Access, Sarepta Therapeutics, USA

Sharad Khusal

Sharad Khusal

Account Executive, Dedalus Group

Frank Liu

Frank Liu

Senior Director, North America Evidence and Value Development (NEVD), EMD Serono

Richard Gliklich

Richard Gliklich

MD & CEO, OM1

David Miller

David Miller

Executive Director, Head of RWE- Patient Safety, Sarepta Therapeutics, USA

Andrew Larsen

Andrew Larsen

Director of Life Sciences Partnership, PicnicHealth

William L Herring

William L Herring

Senior Director, Health Economics, RTI Health Solutions

Prasun Mishra

Prasun Mishra

Founding Director, Chairman of the Board, Agility Pharmaceuticals

Georges De Feu

Georges De Feu

Founder & CEO, Lynxcare

Usha Periyanayagam

Usha Periyanayagam

Head of Clinical Product and RWE, Komodo Health

Jennifer Polinski

Jennifer Polinski

Vice President, Science, Aetion

Tabby Khan

Tabby Khan

Clinical Product Expert, Komodo Health

SPONSORS

Picnic Health
Dedalus
OM1
Komodo Health
Premier Inc.
RTI Health Solutions
Aetion
LynxCare

PARTNERS

Institute of Analytics
Digital Analytics Association
HealthEconomics.Com
This Week in Digital Health

24/7 Customer Support

Asia Office

Phone : +91 20 48598285
[email protected]

USA Office

Phone : +1-888600-6441
[email protected]